Literature DB >> 15638862

Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand.

H Hasegawa1, Y Yamada, H Harasawa, T Tsuji, K Murata, K Sugahara, K Tsuruda, S Ikeda, Y Imaizumi, M Tomonaga, M Masuda, N Takasu, S Kamihira.   

Abstract

Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis in many transformed cells, but not in normal cells, and hence TRAIL has recently emerged as a novel anti-cancer agent. Adult T-cell leukaemia lymphoma (ATLL) is a neoplasm of T-lymphocyte origin aetiologically associated with human T-lymphotropic virus type 1 (HTLV-I), and is resistant to standard anti-cancer therapy. We thus characterized the sensitivity of ATLL cells to TRAIL in this study. Although most primary ATLL cells and cell lines expressed TRAIL death receptors on their surface, they showed only restricted sensitivity to TRAIL. Among the 10 ATLL cell lines examined, one was sensitive, but two had insufficient death-receptor expression, two had an unknown resistant mechanism with abrogation of the death signal upstream of caspase-8, and the remaining five showed attenuation of the signal in both extrinsic and intrinsic pathways by X-linked inhibitor of apoptosis and Bcl-2/Bcl-xL respectively. Furthermore, the level of HTLV-I tax expression was significantly correlated to TRAIL resistance. Interestingly, ATLL cells themselves expressed TRAIL on the cell surface. Constitutive production of TRAIL may offer resistance, thus allowing the development of TRAIL-resistant ATLL cells. Consequently, the resistant mechanism in ATLL cells against TRAIL was assigned to multiple factors and was not explained by a definitive single agent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15638862     DOI: 10.1111/j.1365-2141.2004.05289.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression.

Authors:  M Bleumink; R Köhler; M Giaisi; P Proksch; P H Krammer; M Li-Weber
Journal:  Cell Death Differ       Date:  2010-08-13       Impact factor: 15.828

2.  IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.

Authors:  Juan Carlos Ramos; Phillip Ruiz; Lee Ratner; Isildinha M Reis; Carlos Brites; Celia Pedroso; Gerald E Byrne; Ngoc L Toomey; Valentine Andela; Edward W Harhaj; Izidore S Lossos; William J Harrington
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 3.  HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches.

Authors:  John M Taylor; Christophe Nicot
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

4.  TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.

Authors:  Ching-Huang Wu; Ching-Hai Kao; Ahmad R Safa
Journal:  Hum Gene Ther       Date:  2008-07       Impact factor: 5.695

5.  Relationships of diverse apoptotic death process patterns to mitochondrial membrane potential (Δψ(m)) evaluated by three-parameter flow cytometric analysis.

Authors:  Yuhgi Suzuki; Hiroo Hasegawa; Tomohiro Tsuji; Kazuto Tsuruda; Daisuke Sasaki; Kaori Ishihara; Kazuhiro Nagai; Katsunori Yanagihara; Yasuaki Yamada; Shimeru Kamihira
Journal:  Cytotechnology       Date:  2012-06-06       Impact factor: 2.058

6.  LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway.

Authors:  H Hasegawa; Y Yamada; K Tsukasaki; N Mori; K Tsuruda; D Sasaki; T Usui; A Osaka; S Atogami; C Ishikawa; Y Machijima; S Sawada; T Hayashi; Y Miyazaki; S Kamihira
Journal:  Leukemia       Date:  2011-01-18       Impact factor: 11.528

7.  Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.

Authors:  Hiroaki Taniguchi; Hiroo Hasegawa; Daisuke Sasaki; Koji Ando; Yasushi Sawayama; Daisuke Imanishi; Jun Taguchi; Yoshitaka Imaizumi; Tomoko Hata; Kunihiro Tsukasaki; Naoki Uno; Yoshitomo Morinaga; Katsunori Yanagihara; Yasushi Miyazaki
Journal:  Cancer Sci       Date:  2014-11-05       Impact factor: 6.716

8.  TAS-116 (pimitespib), a heat shock protein 90 inhibitor, shows efficacy in preclinical models of adult T-cell leukemia.

Authors:  Emi Ikebe; Shunsuke Shimosaki; Hiroo Hasegawa; Hidekatsu Iha; Yoshiyuki Tsukamoto; Yu Wang; Daisuke Sasaki; Yoshitaka Imaizumi; Yasushi Miyazaki; Katsunori Yanagihara; Isao Hamaguchi; Kazuhiro Morishita
Journal:  Cancer Sci       Date:  2021-11-27       Impact factor: 6.716

9.  Characteristic expression of HTLV-1 basic zipper factor (HBZ) transcripts in HTLV-1 provirus-positive cells.

Authors:  Tetsuya Usui; Katsunori Yanagihara; Kunihiro Tsukasaki; Ken Murata; Hiroo Hasegawa; Yasuaki Yamada; Shimeru Kamihira
Journal:  Retrovirology       Date:  2008-04-22       Impact factor: 4.602

10.  Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3.

Authors:  Hiroo Hasegawa; Reid P Bissonnette; Mireille Gillings; Daisuke Sasaki; Hiroaki Taniguchi; Hideaki Kitanosono; Kazuto Tsuruda; Kousuke Kosai; Naoki Uno; Yoshitomo Morinaga; Yoshitaka Imaizumi; Yasushi Miyazaki; Katsunori Yanagihara
Journal:  Cancer Sci       Date:  2016-06-22       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.